Success Stories: EB-1A Approved for a Research Fellow in Nebraska in the Field of Hematology & Oncology
Client’s Testimonial:
Thank you all for your help in preparing my application. Your diligence paid off in the end and it was money well spent for me. I have already referred couple of people to contact your firm about getting help in preparing their application.
On January 29th, 2015, We Received Another EB1-A (Alien of Extraordinary Ability) Approval for a Research Fellow in the Field of Hematology & Oncology (Approval Notice)
Position at the Time of Case Filing: Research Fellow
Country of Origin: India
Service Center: Nebraska Service Center (NSC)
State of Residence at the Time of Filing: Nebraska
Approval Notice Date: January 29th, 2015
Processing Time: 5 months, 15 days
For this case we worked with a hematologist and oncology from India with a specialized focus on patterns of breast cancer spread and outcomes research. His highly prolific career thus far had produced 8 peer-reviewed scientific articles, 11 abstracts, and 11 presentations at national and international conferences. He had been cited at least 127 times, primarily by independent researchers at prominent and leading institutions and organizations worldwide. This remarkable citation record clearly indicates the major significance of our client’s work. He had also reviewed at least 6 manuscripts for 3 or more distinctive, internationally-circulated journals. It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of Hematology & Oncology, and that his continued research would substantially and prospectively benefit the United States. An independent recommender affirmed the significance of our client’s research: “[Client] is an important researcher in breast cancer and known for his contributions to the field. His work provides essential benefits to the field of oncology and specifically to the millions of women who will have to face breast cancer at some point in their lives. I am sure that he will continue to be a highly active and significant figure in oncology research.” With the proof and documentation that we provided, his case was approved in 5 months and 15 days.